ASPIRE-FTD is a Phase 1/2 open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN.

Frontotemporal dementia with progranulin mutations research (FTD-GRN)

DOWNLOAD FACT SHEET

WHO CAN PARTICIPATE?

  • Eligible participants must be 30-75 years old, diagnosed with FTD-GRN (confirmed with a genetic test) and have a caregiver who is able to support them (including attending study visits) for the duration of the study (5 years and 3 months).
  • There are other criteria that determine eligibility, which may be discussed with a healthcare provider.
  • Further details about this study can be found at clinicaltrials.gov

ASPIRE-FTD is currently enrolling participants at the following sites. For more information and trial site contact details please visit clinicaltrials.gov

In the coming months we will be updating this list as more sites become active.

You can also contact AviadoBio by phone +1 (888) 591 8117, +44 (0) 203 089 7917 or by email clinicaltrials@aviadobio.com.

USA

Netherlands

  • Amsterdam, Netherlands
    Amsterdam UMC

Poland

Spain

  • Barcelona, Spain, 08036
    Hospital Clinic Barcelona
    Beatriz Bosch
    934 518 240
    BBOSCH@recerca.clinic.cat
  • Valencia, Spain, 46026
    Hospital Universitari i Politecnic La Fe

Sweden

UK

  • Cambridge, United Kingdom, CB2 0QQ
    Cambridge University Hospitals NHS Foundation Trust
    CUH Dementia Trials
    cuh.dementiatrials@nhs.net
  • Cardiff, United Kingdom, CF14 4XW
    University Hospital of Wales

What does study participation involve?

Study participation involves visiting a clinical trial site at different points during the study for screening and follow up, and visiting an expert neurosurgical site for one-time dosing of AVB-101.

Aviadobio team david cooper

“Being relentless means always striving for the best implementation of our plans and ensuring we deliver as individuals, and as a company as whole. We know that patients have limited options and time. Even when the path may not be clear, we navigate a way forward by being bold and tenacious in our decision making.”

David Cooper

Chief Medical Officer